DD: Therapeutic Vaccines & Adjuvants with ImmusanT & Idera Pharmaceuticals
Thursday, October 18 2012
8:00 am – 10:00 am
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA
The Drug Discovery Committee welcomes you to an exciting breakfast meeting with ImmusanT and Idera Pharmaceuticals.
Nicola La Monica, Vice President of Biology at Idera Pharmaceuticals will talk about:
‘Agonists of TLRs 3, 7, 8, and 9 as vaccine adjuvants’
Adjuvants are a key component of vaccines. Toll-like receptors 3, 7, 8, and 9 are endosomal receptors and are expressed on different immune cells. Agonists targeted to these TLRs induce Th-1 type immune responses. Studies on the use of Idera’s proprietary agonists of TLRs as vaccine adjuvants have shown promising results, thereby providing a novel class of adjuvants.
Patrick Griffin, Chief Medical Officer and Sr. VP Development at ImmusanT will discuss their Nexvax2®, the first therapeutic vaccine for patients with celiac disease, presently in clinical development.